Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 11:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 3,594 matching trials from the live ClinicalTrials.gov search.
Conditions
Type 2 Diabetes
Interventions
Targeted Self-Monitoring Of Blood Glucose (SMBG), Provider Training, Patient Education
Other
Lead sponsor
Biomedical Research Institute of New Mexico
Other
Eligibility
18 Years to 85 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Albuquerque, New Mexico
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Peglispro, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
7,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
267
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more
Conditions
Diabetes Mellitus Type 2
Interventions
EGT0001474, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Type 2 Diabetes
Interventions
TNM Device
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Diabetes Mellitus Type 2, Dyslipidemia, Hypercholesterolemia, Obesity
Interventions
removal of omentum
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Bethanechol on Glucose Homeostasis

NCT01434901
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK716155, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
Interventions
GSK189075 oral tablets, GW869682 oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide, rosiglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Jacksonville, Florida + 16 more
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
naveglitazar
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 39 more
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
30 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Not yet recruiting Not applicable Interventional

Argus 2.0 Adoption Study

NCT07425236
Conditions
Diabetes, Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Prediabetes
Interventions
KOS Argus Continuous Glucose Monitoring System
Device
Lead sponsor
KOS Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Mateo, California
Completed No phase listed Observational Accepts healthy volunteers

Improvement of Hyperglycemia/Diabetes in Patients to Improve Safety

NCT06096311
Conditions
Diabetes Mellitus, Type 2
Interventions
Interviews
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cardiovascular Disease
Interventions
Fish Oil and Aspirin
Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
BYM338 10 mg/kg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Anaheim, California • Miami, Florida • Miami Lakes, Florida + 4 more
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, sitagliptin, glimepiride, metformin, placebo albiglutide, placebo sitagliptin, placebo glimepiride
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
317
States / cities
Birmingham, Alabama • Dothan, Alabama • Hueytown, Alabama + 254 more
Completed Not applicable Interventional Results available

P20 Extending Sleep to Reverse Metabolic Syndrome

NCT03596983
Conditions
Metabolic Syndrome
Interventions
Sleep Intervention, Week 2 Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
35 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
66
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more
Conditions
Prediabetic State, Insulin Resistance, Type2 Diabetes, Stress, Adolescent Development, Family Research
Interventions
CookingMatters, Parent Education, Physical Activity, Health Education, Mindfulness-based Stress Reduction, Brief Mindfulness Intervention
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
12 Years to 15 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Fort Collins, Colorado
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, Semaglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Mobile, Alabama • Sheffield, Alabama • Vestavia Hills, Alabama + 47 more
Conditions
Diabetes Mellitus Type 2
Interventions
RO4998452, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
High-Fruit Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
20 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

NCT01165983
Conditions
Diabetes Type 2
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Boston, Massachusetts